Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Ayrignac

Showing results (31-40 of 132) with videos related to

Pageof 14
Sort By:
Expert Review of Neurotherapeutics|June 15, 2019
Assessing the risk of multiple sclerosis disease-modifying therapiesXavier Ayrignac, Philippe-Antoine Bilodeau, Alexandre Prat, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 28, 2020
Frailty in ageing persons with multiple sclerosisXavier Ayrignac, Catherine Larochelle, Mark Keezer, et al.
Inflammation|December 6, 2024
TWEAK and TNFɑ Pro-inflammatory Soluble Cytokines and their Specific Autoantibodies Secretion in Multiple Sclerosis PatientsSylvie Carmona, Jehanne Aghzadi, Thierry Vincent, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 14, 2018
Late activity rebound in non-active multiple sclerosis: A rare eventLucas Corti, Xavier Ayrignac, Clarisse Carra Dalliere, et al.
Journal of the Peripheral Nervous System : JPNS|May 4, 2010
A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathyKarine Viala, Thierry Maisonobe, Tanya Stojkovic, et al.
Neurology and Therapy|April 8, 2024
Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple SclerosisJerome de Seze, Dominique Dive, Xavier Ayrignac, et al.
Multiple Sclerosis and Related Disorders|August 29, 2022
CSF β-amyloid is not a prognostic marker in multiple sclerosis patientsJustine Petitfour, Xavier Ayrignac, Nelly Ginestet, et al.
Retina (Philadelphia, Pa.)|January 6, 2025
EVALUATION OF RETINAL CAPILLARY DENSITY USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY ACCORDING TO ACUTE ISCHEMIC STROKE ETIOLOGIES: A Matched Case-Control Study Stroke and Retinal Capillary DensityEloi Debourdeau, Chloe Chamard, Xavier Ayrignac, et al.
Neurology. Genetics|June 15, 2026
Blood Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Candidate Biomarkers in <i>CSF1R</i>-Related DisorderXavier Ayrignac, Cecilia Marelli, Sylvain Lehmann, et al.
Cerebrovascular Diseases (Basel, Switzerland)|July 18, 2013
COL4A1 mutation revealed by an isolated brain hemorrhageAstrid Corlobe, Elisabeth Tournier-Lasserve, Manuele Mine, et al.
Pageof 14

Showing results (31-40 of 132) with videos related to

Sort By:
Pageof 14
Expert Review of Neurotherapeutics|June 15, 2019
Assessing the risk of multiple sclerosis disease-modifying therapiesXavier Ayrignac, Philippe-Antoine Bilodeau, Alexandre Prat, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 28, 2020
Frailty in ageing persons with multiple sclerosisXavier Ayrignac, Catherine Larochelle, Mark Keezer, et al.
Inflammation|December 6, 2024
TWEAK and TNFɑ Pro-inflammatory Soluble Cytokines and their Specific Autoantibodies Secretion in Multiple Sclerosis PatientsSylvie Carmona, Jehanne Aghzadi, Thierry Vincent, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 14, 2018
Late activity rebound in non-active multiple sclerosis: A rare eventLucas Corti, Xavier Ayrignac, Clarisse Carra Dalliere, et al.
Journal of the Peripheral Nervous System : JPNS|May 4, 2010
A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathyKarine Viala, Thierry Maisonobe, Tanya Stojkovic, et al.
Neurology and Therapy|April 8, 2024
Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple SclerosisJerome de Seze, Dominique Dive, Xavier Ayrignac, et al.
Multiple Sclerosis and Related Disorders|August 29, 2022
CSF β-amyloid is not a prognostic marker in multiple sclerosis patientsJustine Petitfour, Xavier Ayrignac, Nelly Ginestet, et al.
Retina (Philadelphia, Pa.)|January 6, 2025
EVALUATION OF RETINAL CAPILLARY DENSITY USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY ACCORDING TO ACUTE ISCHEMIC STROKE ETIOLOGIES: A Matched Case-Control Study Stroke and Retinal Capillary DensityEloi Debourdeau, Chloe Chamard, Xavier Ayrignac, et al.
Neurology. Genetics|June 15, 2026
Blood Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Candidate Biomarkers in <i>CSF1R</i>-Related DisorderXavier Ayrignac, Cecilia Marelli, Sylvain Lehmann, et al.
Cerebrovascular Diseases (Basel, Switzerland)|July 18, 2013
COL4A1 mutation revealed by an isolated brain hemorrhageAstrid Corlobe, Elisabeth Tournier-Lasserve, Manuele Mine, et al.
Pageof 14